(Q38355582)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

review article

1 reference

title

Molecular imaging of levodopa-induced dyskinesias (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1

Flavia Niccolini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

3

Marios Politis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

15 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

Cellular and Molecular Life Sciences

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

2107-2117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.

29 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Metabotropic glutamate receptors in the basal ganglia motor circuit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Adenosine A2A receptors and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Positron emission tomography provides molecular imaging of biological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Positron emission tomography imaging in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Serotonin in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Dopamine receptor mapping with PET imaging in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Placebo influences on dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Dyskinesia after fetal cell transplantation for parkinsonism: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Brain imaging after neural transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

In vivo imaging of the integration and function of nigral grafts in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Buspirone: What is it all about?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Cholinergic interneuron characteristics and nicotinic properties in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Impairment of reward-related learning by cholinergic cell ablation in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Striatal cholinergic interneurons Drive GABA release from dopamine terminals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Disease-specific patterns of locus coeruleus cell loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Mechanisms for the Modulation of Dopamine D1 Receptor Signaling in Striatal Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Phosphodiesterases in the CNS: targets for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Integrating neurotransmission in striatal medium spiny neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1854-X

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

21 January 2018

1 reference

12 December 2020

Quantification of Human Opiate Receptor Concentration and Affinity Using High and Low Specific Activity [11C]Diprenorphine and Positron Emission Tomography

1 reference

12 December 2020

Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.

1 reference

12 December 2020

Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.

1 reference

12 December 2020

How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?

1 reference

12 December 2020

Dyskinesias in Parkinson's disease: views from positron emission tomography studies

1 reference

12 December 2020

Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia

1 reference

12 December 2020

Amantadine for dyskinesia in Parkinson's disease

1 reference

12 December 2020

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials

1 reference

12 December 2020

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys

1 reference

12 December 2020

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

1 reference

12 December 2020

Sensitization of G Protein‐Coupled Benzodiazepine Receptors in the Striatum of 6‐Hydroxydopamine‐Lesioned Rats

1 reference

12 December 2020

Positron emission tomography neuroimaging in Parkinson's disease

1 reference

12 December 2020

Effects of L-dopa on efflux of cerebral monoamines from synaptosomes

1 reference

12 December 2020

Opioids and motor complications in Parkinson's disease

1 reference

12 December 2020

Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study

1 reference

12 December 2020

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

12 December 2020

Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease

1 reference

12 December 2020

Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenousl-DOPA in the rat, with reference to the involvement of aromaticl-amino acid decar☐ylase

1 reference

12 December 2020

L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study

1 reference

12 December 2020

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

1 reference

12 December 2020

Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study

1 reference

12 December 2020

Dyskinesias following neural transplantation in Parkinson's disease

1 reference

12 December 2020

10.1007/S00018-015-1854-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681866%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference